selected scholarly activity
-
conferences
- Organization of population-based cancer control programs: Europe and the World. Tumori. 623-636. 2009
- 2406. International Journal of Radiation Oncology Biology Physics. S436-S436. 2006
- 10 Acute phase response reactants as an objective measure of mucosal toxicity in head and neck cancer patients undergoing radical radiation therapy with or without concurrent chemo-therapy. Radiotherapy and Oncology. S3-S3. 2006
- Outcomes of previously untreated older patients with multiple myeloma (MM) over time: An analysis of 3 consecutive trials conducted by the NCICCTG, 1983-2003.. Blood. 722A-722A. 2005
- 138 Inflammatory serum markers as an objective measure of radiation mucositis in head and neck cancer. Radiotherapy and Oncology. S41-S41. 2005
- Developing a comprehensive treatment plan for metastatic bone pain: a national consensus process. Journal of Palliative Care. 200-200. 2005
- A study examining epidermal growth factor receptor, p53, and Bcl-2 expression in patients with locally advanced squamous cell carcinoma of the head and neck treated with concomitant chemoradiotherapy. Lung Cancer. S82-S83. 2004
- Evaluation of inflammatory serum proteins as an objective measure of radiation induced mucositis in patients receiving radical radiation with or without concurrent chemotherapy. Radiotherapy and Oncology. S385-S386. 2004
- A study examining epidermal growth factor receptor, p53, and Bcl-2 expression in patients with stage III and IV squamous cell carcinoma of the head and neck treated with concomitant chemo-radiotherapy.. Radiotherapy and Oncology. S40-S40. 2004
- Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I).. Journal of Clinical Oncology. 553S-553S. 2004
- Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases.. Journal of Clinical Oncology. 493S-493S. 2004
- Predictors of high quality clinical practice guidelines in oncology. Annals of Oncology. 147-148. 2004
- A funding program for new anti-cancer drugs in Ontario, Canada, based on quality of evidence and a hierarchy of outcomes. International Journal of Cancer. 300-301. 2002
- Development of Clinical Practice Guidelines: Surgical Perspective. World Journal of Surgery. 1236-1241. 1999
- The preferences of traditional quality of life domains are similar in older versus younger patients with non-Hodgkin's lymphoma.. Blood. 185A-185A. 1999
- Randomized trial of interferon-α maintenance in myeloma patients responding to melphalan and prednisone (MY-6). Cancer Research, Therapy and Control. 129-131. 1998
- Strategies for management of treatment failure in head and neck cancer: Choosing appropriate outcome measures for palliative chemotherapy.. HEAD AND NECK CANCER, VOL 4. 666-675. 1996
- Critical appraisal of interferon therapy for chronic myeloid leukemia.. Blood. 3201-3201. 1995
- DAY-6 BONE-MARROW (D6BM) PREDICTS FOR COMPLETE REMISSION (CR) IN ADULTS WITH ACUTE MYELOID-LEUKEMIA (AML). Blood. A303-A303. 1994
- EVALUATING RISK-BENEFIT IN DRUG TRIALS. Clinical Pharmacology and Therapeutics. 126-126. 1992
- Monitoring compliance and contamination in a chemoprevention trial. Contemporary Clinical Trials. 353-354. 1989
- RECRUITMENT FOR AN EFFICACY STUDY IN CHEMOPREVENTION. Contemporary Clinical Trials. 274-274. 1988
- COMPARISON OF BROMODEOXYURIDINE (BRDU), TRITIATED THYMIDINE(T) AND TRITIATED DEOXYURIDINE (DU) FOR ASSESSING DNA-SYNTHESIS LABELING INDEX (LI) IN TUMOR FRAGMENTS OF SQUAMOUS CARCINOMA OF THE HEAD AND NECK (SCHN). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 26-26. 1988
- PREDICTORS OF RESPONSE TO LOW-DOSE ARA-C. Journal of Cellular Biochemistry. 236-236. 1987
- PROGNOSTIC IMPLICATIONS OF BASOPHIL DIFFERENTIATION IN CHRONIC MYELOID-LEUKEMIA. Clinical Research. A456-A456. 1986
- EXAMINATION OF THE ROLE OF POLYGLUTAMYLATION (PG) IN DETERMINING DIFFERENTIAL FOLINIC ACID (FA) PROTECTION FROM MTX IN HUMAN LYMPHOID-CELL LINES. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 230-230. 1985
- DIFFERENTIAL FOLINIC ACID (FA) PROTECTION OF METHOTREXATE (MTX) TREATED HUMAN LYMPHOID-CELL LINES. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 275-275. 1983
- THYMIDINE AND FOLINIC ACID (FA) PROTECTION FROM METHOTREXATE (MTX) IN HUMAN LYMPHOID-B AND LYMPHOID-T CELL-LINES. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 180-180. 1982
- PURINE (HX) AND THYMIDINE (DTHD) PROTECTION FROM METHOTREXATE (MTX) IN HUMAN-LYMPHOBLASTOID CELL-LINES INVITRO. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 262-262. 1981
- PHYSIOLOGIC LEVELS OF PURINES INFLUENCE METHOTREXATE (MTX) ANTI-TUMOR EFFECT AGAINST L1210 LEUKEMIA INVIVO. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 262-262. 1980
- TREATMENT OF ACUTE MYELOCYTIC-LEUKEMIA - EFFECTS OF EARLY INTENSIVE CONSOLIDATION. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 443-443. 1980
-
journal articles
- Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making. Journal of Clinical Epidemiology. 92:47-57. 2017
- Clinician Engagement and Guideline Development: Enhancing an Evidence-Based Culture for Quality Cancer Care—The 2017 Joseph V. Simone Award and Lecture. JCO Oncology Practice. 13:547-551. 2017
- Innovations in American Society of Clinical Oncology Practice Guideline Development. Journal of Clinical Oncology. 34:3213-3220. 2016
- When is good, good enough? Methodological pragmatism for sustainable guideline development. Implementation Science. 10:28. 2015
- A Time-Trend Economic Analysis of Cancer Drug Trials. Oncologist. 20:729-736. 2015
- Improving the quality of ‘personalized medicine’ research and practice: through an ethical lens. Personalized Medicine. 11:413-423. 2014
- Protecting Human Research Participants: Reading vs Understanding the Consent Form. Journal of the National Cancer Institute. 105:927-928. 2013
- Special Series on Comparative Effectiveness Research: Challenges to Real-World Solutions to Quality Improvement in Personalized Medicine. Journal of Clinical Oncology. 30:4188-4191. 2012
- The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines. Journal of Clinical Epidemiology. 65:526-534. 2012
- Challenges in Knowledge Translation: The Early Years of Cancer Care Ontario’s Program in Evidence-Based Care. Current Oncology. 19:27-35. 2012
- Personalized medicine: a windfall for science, but what about patients?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 183:E1277-E1277. 2011
- Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Quality and Safety. 20:228-236. 2011
- AGREE II: advancing guideline development, reporting and evaluation in health care. CANADIAN MEDICAL ASSOCIATION JOURNAL. 182:E839-E842. 2010
- AGREE II: Advancing guideline development, reporting and evaluation in health care. Journal of Clinical Epidemiology. 63:1308-1311. 2010
- Conceptual and practical challenges for implementing the communities of practice model on a national scale - a Canadian cancer control initiative. BMC Health Services Research. 10:3. 2010
- AGREE II: Advancing guideline development, reporting, and evaluation in health care. Preventive Medicine. 51:421-424. 2010
- Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CANADIAN MEDICAL ASSOCIATION JOURNAL. 182:1045-1052. 2010
- Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CANADIAN MEDICAL ASSOCIATION JOURNAL. 182:E472-E478. 2010
- Evidence‐based clinical practice guideline development: Principles, challenges, and accountability to evidence. Journal of Surgical Oncology. 101:1-2. 2010
- Prognostic Tools for Cancer Survival: A Secondary Role for Quality-of-Life Measurement. Journal of Clinical Oncology. 27:2902-2904. 2009
- The role of guidelines in quality improvement for cancer surgery. Journal of Surgical Oncology. 99:467-469. 2009
- Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. Journal of the Canadian Urological Association. 2:175-175. 2008
- Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding. Health Policy. 86:381-390. 2008
- Guideline Adaptation: An Appealing Alternative to De Novo Guideline Development. ACP journal club. 148:563-563. 2008
- A for Effort: Learning From the Application of the GRADE Approach to Cancer Guideline Development. Journal of Clinical Oncology. 26:1025-1026. 2008
- 6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs. JCO Oncology Practice. 4:2-7. 2008
- Use of systemic therapy in women with recurrent ovarian cancer—Development of a national clinical practice guideline. Gynecologic Oncology. 106:181-192. 2007
- Promoting Best Gynecologic Oncology Practice: A Role For The Society of Gynecologic Oncologists of Canada. Current Oncology. 13:94-98. 2006
- Platinum-Based Concurrent Chemoradiotherapy for Tumors of the Head and Neck and the Esophagus. Seminars in Radiation Oncology. 16:10-19. 2006
- Evaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelines. BMC Medical Research Methodology. 5:8. 2005
- Clinical practice guidelines and healthcare decisions: credibility gaps and unfulfilled promises?. Nature Reviews Clinical Oncology. 2:480-481. 2005
- Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials. Journal of Clinical Oncology. 23:2583-2585. 2005
- Predictors of high quality clinical practice guidelines: examples in oncology. International Journal for Quality in Health Care. 17:123-132. 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. Journal of Clinical Oncology. 23:619-629. 2005
- American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. Journal of Clinical Oncology. 23:619-629. 2005
- Practitioners As Experts: The Influence of Practicing Oncologists “in-the-Field” on Evidence-Based Guideline Development. Journal of Clinical Oncology. 23:113-119. 2005
- An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 45:2471-2476. 2004
- Clinicians' assessments of practice guidelines in oncology: The CAPGO survey. International Journal of Technology Assessment in Health Care. 20:421-426. 2004
- A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism (JCEM). 89:3668-3676. 2004
- International Assessment of the Quality of Clinical Practice Guidelines in Oncology Using the Appraisal of Guidelines and Research and Evaluation Instrument. Journal of Clinical Oncology. 22:2000-2007. 2004
- Delay of Radiation Therapy and Outcomes of Breast Cancer. Journal of Clinical Oncology. 22:1342-1343. 2004
- In Reply:. Journal of Clinical Oncology. 22:1343-1344. 2004
- KEEPING CANCER GUIDELINES CURRENT: RESULTS OF A COMPREHENSIVE PROSPECTIVE LITERATURE MONITORING STRATEGY FOR TWENTY CLINICAL PRACTICE GUIDELINES. International Journal of Technology Assessment in Health Care. 19:646-655. 2003
- European cooperation for clinical practice guidelines in cancer. British Journal of Cancer. 89:S1-S3. 2003
- American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. Journal of Clinical Oncology. 21:2597-2599. 2003
- CONFRONTING THE “GRAY ZONES” OF TECHNOLOGY ASSESSMENT: EVALUATING GENETIC TESTING SERVICES FOR PUBLIC INSURANCE COVERAGE IN CANADA. International Journal of Technology Assessment in Health Care. 19:301-316. 2003
- Clinical-practice guidelines in Europe: time for European co-operation for cancer guidelines. The Lancet Oncology. 4:139-140. 2003
- Does Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review. Journal of Clinical Oncology. 21:555-563. 2003
- Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. International Journal for Quality in Health Care. 15:31-45. 2003
- Negotiating for Change. The Healthcare Manager as Catalyst for Evidence-Based Practice: Changing the Healthcare Environment and Sharing Experience. Healthcare Papers. 3:10-22. 2003
- Role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer. Current Oncology. 10:146-160. 2003
- Association between smoking during radiotherapy and prognosis in head and neck cancer: A follow‐up study. Head and Neck. 24:1031-1037. 2002
- Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology. 20:4083-4107. 2002
- Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 100:2303-2320. 2002
- Critical appraisal of the Minimal Clinical Recommendations (MCR) of the European Society for Medical Oncology (ESMO): challenges for a European framework for the development of clinical practice guidelines. Annals of Oncology. 13:1507-1508. 2002
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002. Journal of Clinical Oncology. 20:3317-3327. 2002
- Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer–a Meta-analysis. Clinical Oncology. 14:203-212. 2002
- A controlled ‘before-after’ study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. British Journal of Cancer. 86:313-321. 2002
- Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma. ACP journal club. 136:144-144. 2002
- Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.. Chronic Diseases and Injuries in Canada. 23:152-156. 2002
- Development and Aftercare of Clinical Guidelines. Journal of the American Medical Association (JAMA). 286:1509-1509. 2001
- Internet Use Among Physicians, Nurses, and Their Patients. Journal of the American Medical Association (JAMA). 286:1451-1452. 2001
- Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle. Journal of Clinical Oncology. 19:3392-3396. 2001
- A National Cancer Institute of Canada Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer. Annals of Oncology. 12:919-922. 2001
- Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head and Neck. 23:579-589. 2001
- Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology. 113:1020-1034. 2001
- ‘Background to clinical guidelines in cancer’: SOR, a programmatic approach to guideline development and aftercare. British Journal of Cancer. 84:1-3. 2001
- Trends in Hormonal Management of Prostate Cancer:. Medical Care. 39:384-396. 2001
- Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. International Journal of Radiation Oncology Biology Physics. 49:917-930. 2001
- Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Current Oncology. 8:16-27. 2001
- Herramientas para la práctica de la medicina basada en la evidencia (y II). Desarrollo de guías de práctica clínica basadas en la evidencia: de abajo-arriba. Medicina Clinica. 116:267-270. 2001
- Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Current Oncology. 8:6-15. 2001
- Treatment of locally advanced squamous cell carcinoma of the head and neck: A summary and overview. Current Oncology. 8:3-5. 2001
- IMPROVING CLINICAL PRACTICE GUIDELINES FOR THE 21ST CENTURY Attitudinal Barriers and Not Technology Are the Main Challenges. International Journal of Technology Assessment in Health Care. 16:959-968. 2000
- The quality of systematic reviews. The BMJ. 321:297-297. 2000
- The quality of systematic reviews - Cochrane Collaboration should ensure equitable participation in management and policy - Reply. The BMJ. 321:298-299. 2000
- Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. The BMJ. 320:537-540. 2000
- The Internet and evidence-based decision-making: a needed synergy for efficient knowledge management in health care.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 162:362-365. 2000
- Drug therapy for chronic myeloid leukaemia. Current Oncology. 7:229-241. 2000
- Herramientas para la práctica de la medicina basada en la evidencia (I). Actualización en recursos de información basados en la evidencia para la práctica clínica. Medicina Clinica. 115:258-260. 2000
- Improving clinical practice guidelines for the 21st century. Attitudinal barriers and not technology are the main challenges.. International Journal of Technology Assessment in Health Care. 16:959-968. 2000
- Optimum radiation fractionation for T1 N0 glottic carcinoma. Current Oncology. 7:91-97. 2000
- Participation patterns of oncologists in the development of clinical practice guidelines. Current Oncology. 7:252-257. 2000
- Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients. Current Oncology. 7:136-148. 2000
- Essence of Evidence-Based Medicine: A Case Report. Journal of Clinical Oncology. 17:1969-1969. 1999
- Evidence-based paradigms and opinions in clinical management and cancer research. Seminars in Oncology. 26:9-13. 1999
- Evidence-based paradigms and opinions in clinical management and cancer research.. Seminars in Oncology. 26:9-13. 1999
- Science, Language, Intuition, and the Many Meanings of Quality of Life. Journal of Clinical Oncology. 17:1651-1651. 1999
- Health care professionals’ familiarity with non-pharmacological strategies for managing cancer pain. Psycho-Oncology. 8:99-111. 1999
- The role of fludarabine in intermediate- and high-risk chronic lymphocytic leukaemia. Current Oncology. 6:90-102. 1999
- Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.. Journal of Clinical Oncology. 16:2834-2839. 1998
- Special issue - HEALNet, a Canadian project - Preface. International Journal of Medical Informatics. 51:69-70. 1998
- The role of group support technology in developing the HEALNet research agenda. International Journal of Medical Informatics. 51:215-219. 1998
- Searching the medical literature for the best evidence to solve clinical questions. Annals of Oncology. 9:377-383. 1998
- Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.. Journal of Clinical Oncology. 16:1226-1231. 1998
- Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.. Cancer Prevention and Control. 2:32-39. 1998
- Should alpha-interferon be included as standard treatment in multiple myeloma?. European Journal of Cancer. 34:22-24. 1998
- Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.. Cancer Prevention and Control. 1:379-392. 1997
- Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.. Cancer Prevention and Control. 1:241-248. 1997
- A guide to interpreting discordant systematic reviews.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 156:1411-1416. 1997
- Surgery in primary supratentorial intracerebral hematoma: a meta-analysis of randomized trials. Acta Neurologica Scandinavica. 95:103-110. 1997
- The clinical practice guideline: an evolving health care technology.. Cancer Prevention and Control. 1:7-8. 1997
- The Ontario Cancer Treatment Practice Guidelines Initiative.. Oncology. 10:19-22. 1996
- Pain Control and the World Health Organization Analgesic Ladder-Reply. Journal of the American Medical Association (JAMA). 275:836-836. 1996
- The role of palliative radiotherapy for bone metastases.. The Canadian journal of oncology. 6 Suppl 1:33-38. 1996
- The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. Journal of the American Medical Association (JAMA). 274:1870-1873. 1995
- Survey of telephone contacts for a Regional Canadian Cancer Society District.. The Canadian journal of oncology. 5:420-426. 1995
- Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: A prospective analysis of 437 cases and its application for designing induction chemotherapy trials. Leukemia Research. 19:861-868. 1995
- Phase II study of subcutaneous rHu-interleukin-2 and rHu-interferon α-2a in previously treated patients with multiple myeloma. Annals of Oncology. 6:721-723. 1995
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 13:2386-2393. 1995
- Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 13:2354-2360. 1995
- Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia. American Journal of Hematology. 48:221-227. 1995
- Implications of using a prognostic index to select therapy for patients with aggressive histology lymphoma.. The Canadian journal of oncology. 5:344-354. 1995
- The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.. Journal of Clinical Oncology. 13:502-512. 1995
- Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.. Journal of Clinical Oncology. 12:2648-2653. 1994
- Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 272:1367-1371. 1994
- Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia. Leukemia Research. 18:659-664. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .5. HOW TO USE AN ARTICLE ABOUT PROGNOSIS. Journal of the American Medical Association (JAMA). 272:234-237. 1994
- Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials.. Seminars in Oncology. 21:311-319. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .4. HOW TO USE AN ARTICLE ABOUT HARM. Journal of the American Medical Association (JAMA). 271:1615-1619. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .3. HOW TO USE AN ARTICLE ABOUT A DIAGNOSTIC-TEST .B. WHAT ARE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS. Journal of the American Medical Association (JAMA). 271:703-707. 1994
- Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 271:389-391. 1994
- Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 271:59-63. 1994
- Evidence-Based Recommendations Against Neoadjuvant Chemotherapy for Routine Management of Patients with Squamous Cell Head and Neck Cancer. Cancer Investigation. 12:662-670. 1994
- The Relationship of the in vivo Cell Cycle Characteristics and Treatment Outcome in Acute Myelogenous Leukemia to the Expression of the FMS and MYC Proto-Oncogenes. Leukemia and Lymphoma. 14:273-278. 1994
- Comparison of the addition of T and N integer scores with TNM stage groups in head and neck cancer. Head and Neck. 15:497-503. 1993
- Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study. American Journal of Hematology. 43:286-290. 1993
- Smoking and Radiation Therapy for Head and Neck Cancer. New England Journal of Medicine. 328:1784-1785. 1993
- The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.. Journal of Clinical Oncology. 11:863-872. 1993
- Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. American Journal of Hematology. 42:359-366. 1993
- CELL-CYCLE CHARACTERISTICS - ALTERABLE DETERMINANTS OF REMISSION DURATION IN A STUDY OF 179 STANDARD RISK NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID-LEUKEMIA. International Journal of Oncology. 2:301-307. 1993
- Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. American Journal of Hematology. 42:147-157. 1993
- Influence of Cigarette Smoking on the Efficacy of Radiation Therapy in Head and Neck Cancer. New England Journal of Medicine. 328:159-163. 1993
- Long Term Outcome of Patients with Acute Myelogenous Leukemia: The Role of Maintenance Therapy, Consolidation Therapy and the Predictive Value of Twoin vitroAssays. Leukemia and Lymphoma. 10:57-66. 1993
- Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.. British Journal of Haematology. 82:555-559. 1992
- Modified adriamycin‐vincristine‐dexamethasone (m‐VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. British Journal of Haematology. 82:555-559. 1992
- Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.. Experimental Hematology. 20:1194-1200. 1992
- A questionnaire to measure morbidity in patients receiving radiation therapy for head and neck cancer. Contemporary Clinical Trials. 13:389-389. 1992
- The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study. British Journal of Haematology. 82:337-346. 1992
- Predicting remission outcome in acute non-lymphocytic leukemia: General principles and their application to residual marrow leukemia. Leukemia Research. 16:511-519. 1992
- The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. British Journal of Cancer. 65:737-743. 1992
- High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia [see comments]. Blood. 79:1037-1048. 1992
- A pilot study of carboplatin augmentation therapy for patients with poor risk acute non-lymphocytic leukemia. Leukemia Research. 16:159-163. 1992
- Optimal conditions for immunohistochemical determination of the in vitro DNA synthesis labelling index with bromodeoxyuridine in head and neck cancer. Cell Proliferation. 24:579-585. 1991
- The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure. British Journal of Haematology. 79:390-397. 1991
- Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia. British Journal of Haematology. 79:33-39. 1991
- Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia [letter]. Blood. 78:849-850. 1991
- RESISTANCE TO PHOTODYNAMIC THERAPY IN RADIATION INDUCED FIBROSARCOMA‐1 and CHINESE HAMSTER OVARY‐MULTI‐DRUG RESISTANT CELLS in vitro. Photochemistry and Photobiology. 54:307-312. 1991
- When is a prognostic factor useful? A guide for the perplexed.. Journal of Clinical Oncology. 9:348-356. 1991
- Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody. Leukemia Research. 15:51-57. 1991
- Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood. 76:2191-2197. 1990
- MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. British Journal of Haematology. 75:340-345. 1990
- Use of screening phase data to evaluate observer variation of sputum cytodiagnosis as an outcome measure in a chemoprevention trial.. Cancer Research. 50:1216-1219. 1990
- Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.. Journal of Clinical Oncology. 8:203-208. 1990
- Assessment of observer variation in measuring the radiographic vertebral index in patients with multiple myeloma. Journal of Clinical Epidemiology. 43:833-840. 1990
- Chemoprevention for lung cancer--evidence for a high degree of compliance.. Cancer Epidemiology. 14:521-525. 1990
- Recruitment for an efficacy study in chemoprevention—The concerned smoker study. Preventive Medicine. 18:700-710. 1989
- Systemic adjuvant therapy for node-negative breast cancer.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 141:381-387. 1989
- Etretinate Blood Levels in Monitoring of Compliance and Contamination in a Chemoprevention Trial. Journal of the National Cancer Institute. 81:795-798. 1989
- Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study. British Journal of Haematology. 71:493-497. 1989
- Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study. Blood. 73:255-262. 1989
- Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.. Journal of Clinical Oncology. 6:963-968. 1988
- Prognostic implications of basophil differentiation in chronic myeloid leukemia. American Journal of Hematology. 27:110-114. 1988
- CELL-CYCLE AND DRUG SENSITIVITY STUDIES OF LEUKEMIC-CELLS THAT APPEAR RELEVANT IN DETERMINING RESPONSE TO CHEMOTHERAPY IN ACUTE NONLYMPHOCYTIC LEUKEMIA. Seminars in Oncology. 14:217-225. 1987
- Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia.. Seminars in Oncology. 14:217-225. 1987
- Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.. Journal of Clinical Oncology. 5:722-730. 1987
- Bench-to-bedside research and the human tumor stem-cell assay--bridging the credibility gap.. Journal of Clinical Oncology. 4:1730-1731. 1986
- Classifying acute leukemia by immunophenotyping: a combined FAB- immunologic classification of AML. Blood. 68:1355-1362. 1986
- Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology. 18:257-260. 1986
- High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study. American Journal of Hematology. 23:131-134. 1986
- The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia. Blood. 68:900-905. 1986
- Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements. British Journal of Haematology. 63:625-636. 1986
- Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer.. Journal of Clinical Oncology. 4:1121-1126. 1986
- Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.. Journal of the National Cancer Institute. 70:455-459. 1986
- Influence of the poly (ADP‐ribose) polymerase inhibitor 3‐aminobenzamide on macrophage and granulocyte differentiation of HL‐60 cells. American Journal of Hematology. 21:67-78. 1986
- Survival results from a phase III study of simultaneous versus 1‐hour sequential methotrexate—5‐fluorouracil chemotherapy in head and neck cancer. Head and Neck. 8:146-152. 1986
- Cytarabine-induced palmar-plantar erythema. JAMA dermatology. 121:1240b-1241. 1985
- Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines. Cancer Chemotherapy and Pharmacology. 15:111-114. 1985
- Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate. Cancer Chemotherapy and Pharmacology. 15:105-110. 1985
- The treatment of patients with acute nonlymphocytic leukemia in remission.. Seminars in Oncology. 12:91-97. 1985
- Treatment of patients with acute nonlymphocytic leukemia in relapse: A leukemia intergroup study. American Journal of Hematology. 19:167-176. 1985
- Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy. European Journal of Cancer. 21:563-571. 1985
- Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report.. Journal of the National Cancer Institute. 69:240-241. 1985
- Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemia. Blood. 65:142-148. 1985
- Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside. British Journal of Haematology. 58:19-32. 1984
- Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. European Journal of Cancer. 20:1061-1068. 1984
- Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence?. Journal of the National Cancer Institute. 68:465-469. 1984
- Relationship between the per cent of marrow cells in S phase and the outcome of remission‐induction therapy for acute nonlymphocytic leukaemia. British Journal of Haematology. 56:399-407. 1984
- Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology. 12:125-130. 1984
- Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.. Journal of Clinical Oncology. 1:787-792. 1983
- The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia. American Journal of Hematology. 15:227-235. 1983
- Therapy of Secondary Acute Nonlymphocytic Leukemia. New England Journal of Medicine. 308:1295-1296. 1983
- Therapy of Secondary Acute Nonlymphocytic Leukemia with Cytarabine. New England Journal of Medicine. 308:21-23. 1983
- Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines.. Journal of the National Cancer Institute. 66:2051-2059. 1982
- The treatment of acute myelocytic leukemia in patients 30 years of age and younger. American Journal of Hematology. 13:189-198. 1982
- High-dose cytosine arabinoside: Clinical response to therapy in acute leukemia. Pediatric Blood and Cancer. 10:239-250. 1982
- Modification of in vivo methotrexate antitumor effect in L1210 leukemia by induced impairment of purine salvage. Biochemical Pharmacology. 30:869-874. 1981
- Studies with a 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)-resistant L1210 leukemia cell line without cross-resistance to methotrexate. Biochemical Pharmacology. 29:2241-2245. 1980
- Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo.. Journal of the National Cancer Institute. 64:231-236. 1980
- A Complement independent erythropoietic inhibitor acting on the progenitor cell in refractory anemia. American Journal of Medicine. 61:572-578. 1976
- Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 114:1108-1112. 1976
- When is Good, Good Enough? Methodological Pragmatism for Sustainable Guideline Development: Democratization of Processes for Setting Methodological Standards for Trustworthy Clinical Practice Guidelines. Journal of Oncology Translational Research. 02:1-2.